BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:EPFL BioE Talks SERIES  "Systems Biologics: Protein Engineering on
  the Proteome Scale"
DTSTART:20210301T160000
DTEND:20210301T163000
DTSTAMP:20260916T063934Z
UID:442cdec12fe28ebe6241f02742e5576b0a9332078b17f4de0fb3b10d
CATEGORIES:Conferences - Seminars
DESCRIPTION:Prof. Sachdev Sidhu\, University of Toronto (CAN)\nWEEKLY EPFL
  BIOE TALKS SERIES\n \n(note that this talk is number one of a double-fea
 ture seminar - see details of the second talk here)\n\nAbstract:\nOver the
  past two decades\, genomics technologies have revolutionized basic resear
 ch and are also having a significant impact on understanding\, predicting 
 and diagnosing disease. Over the same period\, the biologics revolution\, 
 lead by therapeutic antibodies\, has greatly expanded our ability to targe
 t proteins that drive cancer and other diseases. To date\, however\, the a
 cademic genomics revolution and the industrial biologics revolutions have 
 not been combined\, so that the vast amounts of data generated by genomics
  technology have not been effectively translated to drug development\, whi
 ch remains a slow\, case-by-case process. In the Donnelly Centre at the Un
 iversity of Toronto\, we have established the Toronto Recombinant Antibody
  Centre (TRAC) to combine large-scale systems biology approaches with the 
 discovery and development of new antibody drugs. Moreover\, we have establ
 ished the Accelerator Centre for Donnelly Collaborations (AcDC) to enable 
 rapid and efficient development of therapeutic biologics through a collabo
 rative network of industrial partners and financiers. The efficient pipeli
 ne exemplified by the basic research of the Donnelly Centre\, connected to
  the translational science of the TRAC\, and the commercialization of the 
 AcDC\, constitutes a new model for research and drug development\, which w
 e have termed “Systems Biologics”. Through this model\, cutting-edge s
 ystems biology basic research can be seamlessly translated into systems bi
 ologics: novel\, multi-functional drugs and diagnostics that take advantag
 e of the complexities of human biology revealed by genomics data.\n\nBio:\
 nDr. Sidhu is a Professor in the Department of Molecular Genetics and the 
 Donnelly Centre at the University of Toronto. Dr. Sidhu is also the foun
 der of the Toronto Recombinant Antibody Centre (TRAC) and the Centre for C
 ommercialization of Antibodies and Biologics (CCAB). Dr. Sidhu joined the
  Donnelly Centre for Cellular & Biomolecular Research in 2008 after ten 
 years as a Principal Investigator in the Department of Protein Engineering
  at Genentech. He returned to academia after a distinguished career at Gen
 entech where he led the development of its phage display technology. Dr. S
 idhu's research is primarily focused in the field of protein engineering a
 nd technologies that explore and shape protein and antibody structure and 
 function\, with the aim of crafting better therapies for cancer and other 
 diseases. He has a wealth of experience in commercial antibody discovery. 
 He has published more than 200 scientific papers and is a co-inventor on m
 ore than 50 patents granted or filed with the US patent office. Dr. Sidhu 
 was the recipient of the 2015 Christian B. Anfinsen Award of the Protein S
 ociety for significant technological achievements in protein research.\n\n
 \n\nZoom link (with registration) for attending remotely: https://go.epfl.
 ch/EPFLBioETalks\n\n\nIMPORTANT NOTICE: due to restrictions resulting from
  the ongoing Covid-19 pandemic\, this seminar can be followed via Zoom web
 -streaming only\, (following prior one-time registration through the link 
 above).
LOCATION:via Zoom web-streaming only\, due to Covid-19 pandemic https://go
 .epfl.ch/EPFLBioETalks https://go.epfl.ch/EPFLBioETalks
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR